Recently, Skynor Medical completed RMB tens of millions of Serious A funding led by Sinopharm Capital. After this investment, Sinopharm Capital will take the advantages of Sinopharm platform to provide Skynor with post-investment value-added services of team builds, products registration and sales&marketing to form the strategic synergy.
Skynor Medical, which founded in 2014 and located in Shanghai International Medical Park, received angel round investment of RMB millions from Shunrong Capital in 2014. In 2016, it obtained RMB tens of millions of Pre-A round investment led by Zjventure. Skynor Medical is a company focused on the development of cutting-edge vascular products with minimally invasive, including two major product lines of neurovascular intervention and peripheral intervention, dedicated to provide a complete treatment solution for patients with stroke, peripheral vascular disease .
Both the thrombectomy stents and the peripheral vascular stents have been stepped into NMPA registration stage, and the clinical enrollment speed is leading in China. So far till now, the company has applied for more than 20 patents.
Stroke kills 1.7 million people every year in China, making it the first cause of death among Chinese residents. Ischemic stroke accounts for about 80% of all strokes, among which acute cerebral infarction caused by large vessel occlusion is often dangerous, with high mortality rate and easy disability. The key to the treatment of ischemic stroke is to open the blocked blood vessels as soon as possible. Traditional intravenous thrombolysis has a low rate of vascular recanalization in cerebral infarction with large vessel occlusion, and stent thrombectomy has provided a groundbreaking treatment for stroke patients. In 2015, China and the United States updated the guidelines for the treatment of ischemic stroke, and stent thrombectomy was regarded as the highest recommendation, and it was listed as the "Top Ten Medical Technology Innovations in 2016" by Cleveland Center. Neurosurgical intervention has become a minimally invasive treatment field with great growth potential. In 2017, the actual number of thrombectomy operations in China was less than 15,000, with a penetration rate of only 0.56%, showing great development potential. It is estimated that the market scale of neurosurgical intervention in China will exceed RMB 8 billion in 2025.
The vascular diseases of lower limbs mainly include diabetic foot, stenosis or occlusion of iliac, femoral, popliteal and subgenital arteries, etc. According to the data in 2017, the prevalence of adult diabetes in China is more than 10%, and there are more than 100 million diabetes patients in the country. According to the detection rate of 35% and the lower limb disease rate of 20%, there are more than 7.2 million patients with lower limb disease.
Post time: Jan-04-2019